Michael Makris Questions FVIII Aurora’s Potential to Transform Hemophilia A Gene Therapy
Michael Makris, Professor of Haemostasis and Thrombosis at University of Sheffield, Editor-in-Chief of Research and Practice in Thrombosis and Haemostasis, shared an insightful post on LinkedIn:
“A potentially important finding was reported in a letter to the editor in today’s New England Journal of Medicine.
The authors reported a gain of function mutation in FVIII, called FVIII Aurora.
This can be thought of as analogous to FIX Padua which has transformed hemophilia B gene therapy.
Will FVIII Aurora transform hemophilia A gene therapy?
Having read the letter and the supplement, I have a number of questions/comments:
1. The thrombotic history is fairly extreme. No information about treatment with anticoagulants is given. Was this patient never treated for the multiple severe thrombotic episodes?
2. Only 2 FVIII levels are given in the supplement, and they were 370 and 615%. The patient’s clinical circumstances when these blood samples were drawn are not given. FVIII is an acute phase reactant, so knowing the status of the patient when they were drawn is critical.
3. In the letter it is stated the FVIII levels were between 300-900%. Whenever I see factor levels ending in such round numbers, I become suspicious. Did this patient really have a level that was precisely 900%? Why were the authors not asked to provide all the FVIII levels from this patient?
4. Although the patient and grandparents are deceased, we are not told if there are any other relatives with this mutation alive.
5. It is surprising that the NEJM has published this without the expression data from the recombinant variant.
Potentially this is very important, but until we see the recombinant protein expression data, we will not know how important.”
Read the full article in The New England Journal of Medicine.
Stay updated on all science in the field of bleeding disorders with Hemostasis Today.
-
Oct 10, 2025, 16:15Roshan PK: Breaking Down Pulmonary Embolism Treatment By Risk Level
-
Oct 10, 2025, 12:21Chris Barber Echoes PPTA’s Call to Recognize the Lifesaving Work of Plasma Collection Teams Worldwide
-
Oct 10, 2025, 12:14William Aird: Thalassemia Trait is a Quiet Experiment of Nature
-
Oct 9, 2025, 19:53Wilfried Dinh: Top 10 Thrombosis And Antithrombotic Therapy Papers Of 2024
-
Oct 9, 2025, 13:12Abdul Mannan - Ferritin After IV Iron: Timing Matters
-
Oct 10, 2025, 12:23Bhavya Venkatesh: Talin Autoinhibition Is Required For Normal Hemostasis
-
Oct 10, 2025, 12:19Divyaswathi Citla Sridhar: Excited to Share Our Multicenter Study on Platelet Function Disorders, Now Published
-
Oct 10, 2025, 12:18Roberta Gualtierotti: We Evaluated Different Variables of the Cleaved HK Method in C1-Inhibitor Defects
-
Oct 10, 2025, 12:17Jamie Madrigal And The Team - Mathematical Analysis Of Emicizumab: Affinity-Driven Complex Formation And Lipid-Surface Reactions
-
Oct 10, 2025, 03:09Giuseppe Lippi: We Show Here That Red Light Therapy Offers Promise in High-Risk Patients
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 10, 2025, 03:10Marilena Vrana: Plasma-Derived Medicines Are a Clear Example of Why A One-Size-Fits-All Approach Won’t Work
-
Oct 10, 2025, 03:07Nancy Di Salvo: It's IPAW 2025, How Could I Not Take a Moment to Thank Every Single Plasma Donor Out There?
-
Oct 10, 2025, 03:06Anita Brikman: Increasing Awareness of The Ongoing Need for Plasma Donors Is Vital to Ensuring Patient Access and Continuity of Care
-
Oct 10, 2025, 03:04Stephen Cornelissen: A New Plasma Drop Has Been Added to Lifeblood’s Blood Supply Tracker
-
Oct 10, 2025, 02:12Bethany Samuelson Bannow Welcomed to Department of Hematology and Medical Oncology at the Cancer Institute Cleveland Clinic